California–based Edwards Lifesciences Corp. has received FDA clearance for its HemoSphere advanced monitoring platform.

The device monitor provides clinicians with more information on a patient’s hemodynamics, the factors that manage blood flow, to help them make clinical decisions.

The product is compatible with the company’s Swan-Ganz pulmonary artery catheter and oximetry catheters.

The device is also approved for commercial use in Europe, Japan, Australia and New Zealand. — Cynthia Jessup